Physician profile
Marvin Ashford
NPI 1518907807
$6,830.39
in general payments reported to CMS, 2019-2025
34 companies · $780 in 2025
The $780 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $755 · 2021: $1,413 · 2022: $667 · 2023: $884 · 2024: $784 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.43 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,597.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $721.12 | 2019-2023 | Xarelto |
| Amgen INC. | $552.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.53 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $463.35 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $420.43 | 2021-2025 | Verquvo |
| Pfizer INC. | $405.95 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $355.70 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $274.89 | 2019-2024 | |
| Astellas Pharma US INC | $261.51 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $157.41 | 2019-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $109.29 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $105.11 | 2019-2021 | |
| Genentech USA, INC. | $97.33 | 2021 | |
| Abbott Laboratories | $93.69 | 2021-2024 | Cardiomems |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $93.50 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $68.68 | 2023-2025 | |
| Irhythm Technologies, INC. | $66.47 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Gilead Sciences, INC. | $63.65 | 2019 | |
| Innovation Technologies INC | $62.99 | 2025 | Irrisept |
| Esperion Therapeutics, INC. | $58.94 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $45.41 | 2023 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $34.30 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $34.02 | 2024 | Arcalyst |
| Abiomed | $30.55 | 2025 | |
| Terumo Medical Corporation | $26.45 | 2025 | Angio-Seal |
| Kestra Medical Technology Services, INC. | $22.66 | 2025 | Assure Wcd |
| Lundbeck LLC | $19.26 | 2019 | |
| Medtronic Vascular, INC. | $18.32 | 2019 | |
| Bridgebio Pharma, INC. | $16.79 | 2025 | Attruby |
| Philips North America LLC | $15.58 | 2020 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Tactile Systems Technology INC | $13.90 | 2022 | |
| Boston Scientific Corporation | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Ashford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.